Abstract
Background Chronic liver disease (CLD) is a progressive condition that can advance to cirrhosis and acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ dysfunction, critical illness, and high mortality. ACLF is driven by systemic inflammation, often without overt infection, suggesting alternative immune activation pathways, including microbial translocation. While intestinal perturbations, bacterial translocation, and immune dysfunction are hallmarks of ACLF, the specific microbial contributors remain unclear.
Objective To investigate relationships between gut microbiome alterations, systemic inflammation, and clinical markers of disease severity across the cirrhosis spectrum.
Design This cross-sectional, prospective study analysed faecal microbiota, plasma bile acids, urinary and plasma metabolites, gut and systemic inflammation and translocation markers, and monocyte dysfunction, in a well-phenotyped cohort of ACLF patients, decompensated and stable cirrhosis, compared to healthy individuals.
Results Advanced stages of cirrhosis exhibited higher Enterococcus abundance, correlating with systemic inflammation, particularly in ACLF patients. Anaerobic commensal genera (Roseburia, Ruminococcus, and Faecalibacterium) were significantly lower. Lower urinary hippurate and trimethylamine N-oxide (TMAO) levels, linked to reduced microbial metabolism, paralleled these microbiome changes. Systemic inflammatory markers suggested parallel gut barrier dysfunction and microbial translocation in advanced cirrhosis.
Conclusion Intestinal Enterococcus abundance, in advanced cirrhosis with greater antibiotic exposure, is a potential driver of gut barrier inflammation and dysfunction, and systemic immune activation. Further research into tailored microbiome-targeted therapies, including prebiotics, probiotics, phages and focused antibiotic use may prevent Enterococcus dominance, restore gut-liver axis homeostasis, and mitigate disease progression in cirrhosis.
What is already known on this topic
CLD can progress to ACLF, a life-threatening syndrome with high mortality rates characterised by systemic inflammation, impaired phagocytosis and immune dysfunction with associated multiple organ failure.
The gut microbiome’s role in underpinning the gut-liver axis is recognised, with microbial perturbations and gut barrier dysfunction associated with CLD, yet the exact microbiome changes and their link to inflammatory pathways remain unclear.
What this study adds
This study reveals that Enterococcus significantly increases with CLD severity and antibiotic use and correlates with markers of systemic inflammation and gut barrier dysfunction.
Reductions in obligate anaerobe commensal bacteria, such as Roseburia and Faecalibacterium, are observed, alongside depressed levels of key microbial metabolites, including hippurate and TMAO, across CLD stages.
These changes suggest that Enterococcus predominance and gut microbiome perturbations driven by factors including disease severity and antibiotic use may actively drive inflammation and impaired monocyte function in CLD.
How this study might affect research, practice, or policy
Findings indicate that Enterococcus and wider gut microbiome perturbations provide a rationale for targeting as therapeutic strategies to modulate the gut-liver axis in CLD.
This highlights the potential of microbiome-focused interventions, such as faecal microbial transplantation, probiotics, prebiotics or phages, to improve gut health, reduce gut and systemic inflammation, and ultimately mitigate cirrhosis-related complications.
Future research and development of targeted microbiome therapeutics and rapid infection diagnostics may positively influence CLD management, including a focus on antimicrobial stewardship and informing clinical guidelines whilst improving patient outcomes.
Competing Interest Statement
LAE has undertaken consultancy for EnteroBiotix. DLS has undertaken consultancy for Norgine Pharmaceuticals Ltd, EnteroBiotix, MRM Health, Apollo Therapeutics, Genfit and Satellite Biosciences. RPV reports Honoraria from Novo Nordisk, Amarin UK and AstraZeneca. AS has delivered paid lectures for Bristol Myers Squibb. VCP has undertaken consultancy for Norgine Pharmaceuticals Ltd, Alfasigma S.p.A., AstraZeneca and Menarini Diagnostics Ltd. MD, LH, RK, IJC, ALG, GR, SS, SC, KB have no conflicts.
Funding Statement
The observational study was adopted to the National Institute for Health Research (NIHR) Clinical Research Network (CRN) portfolio supporting participant screening and recruitment by the Liver Research and Anaesthetics Critical Care Emergency and Trauma Teams at Kings College Hospital NHS Foundation Trust. VCP was supported by a New Investigator Award from the Intensive Care Foundation (Registered charity number: 2940178) and Clinical Research Network South London Principal Investigator Strategic GreenShoot Research Delivery and Development Funding. The clinical trial was funded through an investigator-initiated study grant awarded by Norgine Pharmaceuticals UK Limited to Kings College London. Infrastructure to support the trial was also provided by the Medical Research Council (MRC) Centre for Transplantation, Kings College London UK MRC grant no. MR/J006742/1. Laboratory assays were also part funded by a generous donation from a Liver Service User to the Kings College Hospital Institute of Liver Studies and Transplantation Charity Research Fund, Kings College Hospital Charity (Registered charity number: 1165593). MS, BA, MEM, MM, SC and VCP were supported and bioinformatic analyses were part funded by the Foundation for Liver Research (Registered charity number: 268211/1134579). LJH is supported by Wellcome Trust Investigator Award (220876/Z/20/Z); the Biotechnology and Biological Sciences Research Council (BBSRC), Institute Strategic Programme Gut Microbes and Health (BB/R012490/1), and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10356, and the BBSRC Institute Strategic Programme Food, Microbiome and Health BB/X011054/1 and its constituent project BBS/E/QU/230001B. MT Acknowledges support from the NIHR-Imperial Biomedical Research Centre and the Medical Research Council Precision Medicine Award (MR/R014019/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The observational study was granted approval by the NHS Health Research Authority NRES Committee London Westminster [REC reference: 12/LO/1417] and local sponsor Research and Development department (KCH12-126). Ethical approval for the interventional trial was obtained from NHS Health Research Authority NRES Committee South Central-Oxford C (Bristol) [REC reference: 14/SC/0088] and from the Medicines and Healthcare products Regulatory Agency for Clinical Trial Authorisation [EudraCT number: 2013-004708-20; ClinicalTrials.gov NCT02019784]. The studies were conducted in compliance with the principles of the Declaration of Helsinki (1996), principles of Good Clinical Practice, Research Governance Framework and where relevant, the Medicines for Human Use (Clinical Trial) Regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
